Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Cellink in a directed new issue of shares of MSEK 100
Mandate

Vinge has advised Cellink in a directed new issue of shares of MSEK 100

June 05, 2018 Capital Markets and Public M&A

Vinge has advised Cellink AB (publ) in connection with a directed new issue of shares to Swedish and internationally well-reputed investors such as the Swedish Fourth AP Fund (AP4), Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.

The subscription price in the amount of SEK 132.50 has been determined through a so called accelerate bookbuilding procedure. As a result of the new issue, Cellink will receive approximately MSEK 100. The proceeds generated by the new issue of shares will be used, among other things, in order to perform acquisitions in accordance with Cellink’s growth strategy, continued global expansion and future development of its product portfolio. Carnegie Investment

Bank has acted as financial advisor and sole bookrunner.

Vinge’s team consisted of partner Anders Strid together with, among others, Wibeke Sorling and company assistant Camilla Andersson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025